Thomas Weisel rates ViroPharma at outperform

ViroPharma Inc. was given an initial research coverage rating of outperform by Thomas Weisel Partners analyst Joe Slavinksy on expected continued growth of Vancocin, the only approved treatment for Clostridium difficile-associated disease. Weisel forecasts 2006 Vancocin sales of $162 million, growing to $239 million by 2008. Shares of the Exton, Pa., pharmaceutical company were up 5 cents, or 0.24%, at $20.43 on volume of 1,274,680 shares versus the three-month running average of 2,512,850 shares. (Nasdaq: VPHM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.